WuXi Biologics signed manufacturing deals to support Viridian’s thyroid eye disease program, reflecting continued demand for CDMO capacity even as providers navigate policy and regulatory uncertainty. The contract adds to WuXi’s recent slate of agreements with U.S. biotechs this year. Service-provider momentum is particularly relevant for later-stage global supply planning, where lead times for biologics drug substances and drug products can materially affect Phase 3 timelines and launch readiness. Deals like these also signal that buyers are increasingly prioritizing manufacturing continuity. While financial terms were not disclosed, the collaboration places WuXi in the workflow for an indication where dosing logistics and long-term treatment schedules heighten the need for reliable scale-up execution.